Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).  Preliminary analysis demonstrates that the trial has met its primary endpoint.

FREEDOM-M was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness.  The study enrolled 349 patients who were not receiving any approved PAH medication, with the population for the primary analysis consisting of the 228 patients who had access to the 0.25 mg tablet at randomization.  These patients were administered oral treprostinil or placebo twice daily, with the doses titrated to effect over the course of the 12-week trial.  The majority of patients were in World Health Organization (WHO) Functional Class II (~33%) and Class III (~66%) of varied etiologies, including idiopathic or familial PAH (~75%), collagen vascular disease associated PAH (~19%), and PAH associated with HIV or other associated conditions (~6%).  The patients’ mean baseline six-minute walk distance (6MWD) was approximately 330 meters.

The primary efficacy endpoint of the trial was the change in 6MWD at 12 weeks for the 228 patients.  Preliminary analysis of the FREEDOM-M results demonstrates that those patients receiving oral treprostinil improved their median 6MWD by approximately 23 meters (p=0.0125, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial’s pre-specified statistical analysis plan) as compared to patients receiving placebo.  The median change from baseline was 25 meters for oral treprost
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Aug. 10, 2011 GNS Healthcare, Inc., (GNS) ... personalized medicine to improve human health, today announced ... Bristol-Myers Squibb Company (NYSE: BMY ) ... and biomarkers in the area of immuno-inflammation.  Utilizing ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) announced today ... will present at the Wedbush Securities 2011 Life Sciences Management ... on Tuesday, August 16, 2011. This presentation ... Relations section of Ardea,s website at www.ardeabio.com . Please ...
Cached Medicine Technology:GNS Healthcare Announces Collaboration With Bristol-Myers Squibb 2Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference 2
(Date:8/29/2014)... new report released yesterday by the Mental Health ... mental health training and education that police personnel ... prominent issue for Canada,s police community, and today,s ... law enforcement and people with mental illnesses," says ... with an interest in the area of police ...
(Date:8/29/2014)... AURORA, Colo. (Sept. 2, 2014) A team of ... has reported the breakthrough discovery of a process to ... patients. These findings could have implications that extend beyond ... and autoimmune diseases., In an article published ... the Charles C. Gates Center for Regenerative Medicine and ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 LiveOps, Inc., ... service solutions, today announced that LiveOps has been selected ... Association's (MDA) Show of Strength Telethon for the third ... raises money and awareness to support MDA’s mission to ... aggressive and sometimes fatal muscle disease. This year’s program ...
(Date:8/29/2014)... Steven Reinberg HealthDay Reporter ... The vast majority of American babies are getting the ... federal health officials said Thursday. More than 90 ... measles, mumps, and rubella (MMR); polio; hepatitis B and ... Control and Prevention. "Nationally, vaccination among children 19 ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... be slippery, especially when wearing socks. Also, many patients ... ambulatory problems, poor balance, surgery recovery, Alzheimer’s, etc. Two ... in order to optimize patient safety. , This special ... medical-facility floors. It also keeps patients who are relegated ...
Breaking Medicine News(10 mins):Health News:Report advocates improved police training 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3
... drug advertisements are appearing on television, the bulk ... companies spend annually to market their products is ... medical students. , A literature review by ... and the Regenstrief Institute, Inc. published in the ...
... study suggests it boosts production of bone-eroding cells , , MONDAY, ... by millions of diabetes patients, may contribute to bone loss, ... fear that, over the long term, Avandia (rosiglitazone) may speed ... dangerous and even fatal fractures. , The findings appear in ...
... was one of the,five deadliest storms in United ... $86 billion.) The total fatalities were estimated at ... the West Coast, CJ (of CJ,s Functional,Fitness) has ... techniques, with,old school parental inspirations, to counsel the ...
... trigger symptoms, experts warn , SATURDAY, Dec. 1 (HealthDay News) ... the season of sneezing, congestion and other woes for people ... the American Academy of Allergy, Asthma & Immunology (AAAAI). , ... they say. , "Whether it,s feasting on holiday meals, setting ...
... The third annual,Saddleback Global Summit on AIDS & The Church ... to the more than 1,700 attendees for,the Church to lead ... with HIV/AIDS need to have the invisible God made visible ... are many things we,don,t know about this epidemic, but what ...
... 30 A recent press release,incorrectly attributed findings ... out-of-pocket expenses of family caregivers. Today,SarahCare issued the ... recent press release issued by SarahCare corporate did ... taken from the "Evercare(R)/NAC,Study of Caregivers -- What ...
Cached Medicine News:Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:Diabetes Drug Avandia Could Weaken Bones 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 3Health News:'Tis the Season For Allergy, Asthma 2Health News:Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E 2Health News:Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E 3
... Series II Power Supplies. The EPS-2000-II, ... EPS-6000-II. These high-voltage power supplies offer ... power operating modes, with automatic crossover ... current/300 watts maximum power (except for ...
... power supply, 100-120 and 220-240 V, provides ... 1-500 W. The two-line, 16-character LCD allows ... of run progress. Built-in infrared capability allows ... a built-in switch when using either electrical ...
... PowerPac Basic power supply, 100-120 ... of 10-300 V, 4-400 mA, ... contains a built-in switch when ... the appropriate power cord. Power ...
... PRODUCT SPECIFICATIONS Form: Granular, free flowing powder EEO(-m r ... Point (3%): less than or equal to 31C ... 76C Gel Strength (3%): greater than or equal to ... or equal to 1000 gm/cm 2 Moisture: less ...
Medicine Products: